Identification of residues involved in binding of IL5 to βcom using βIL3 and βcom chimeras  by Czabotar, Peter E et al.
Identi¢cation of residues involved in binding of IL5 to Lcom using LIL3
and Lcom chimeras
Peter E. Czabotara;*, John Hollandb, Colin J. Sandersona
aDivision of Molecular Immunology, School of Biomedical Sciences, Curtin University of Technology, Level 5 MRF Building, Rear 50 Murray Street,
Perth, W.A. 6000, Australia
bUrological Research Centre, QEII Medical Centre, Nedlands, W.A. 6009, Australia
Received 13 September 1999
Abstract In mice there are two forms of the beta chain used in
the IL3 receptor system, Lcom and LIL3. Lcom is used by the IL3,
IL5 and GM-CSF receptors whereas LIL3 is only used in the IL3
receptor. In this work an assay was developed to identify residues
of LIL3 that restrict IL5 activity. It was found that such residues
reside within the 2nd CRM of the molecule. Furthermore, when
residues in the LIL3 BP-CP loop were replaced with Lcom sequence
a form of LIL3 was produced that was able to respond to IL5.
This region is also responsible for IL3 binding to LIL3 in the
absence of alpha chain. It is therefore an important structural
motif of Lcom and LIL3 responsible for both ligand interaction and
specificity.
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1. Introduction
In humans, the receptor complexes for IL3, IL5 and GM-
CSF are composed of a cytokine speci¢c alpha chain and a
shared beta chain (Lcom). The shared usage of Lcom de¢nes
these cytokines as members of a subgroup of the cytokine
family. They also share similarities in biological activity and
structure. In particular, all three have a conserved glutamic
acid within their ¢rst helix which acts as a contact point for
Lcom [1^4]. Lcom itself does not display any measurable binding
for these cytokines in the absence of alpha chain. It does,
however, provide an a⁄nity conversion for the ligand/alpha
chain complex. For IL3 the a⁄nity is increased 500^1000-fold
[5], GM-CSF 10^100-fold [6] and IL5 only 2^3-fold [7,8].
In mice there is an isoform of Lcom that is speci¢c for IL3
(LIL3). Unlike Lcom, LIL3 is able to bind IL3 in the absence of
alpha chain. Despite these functional di¡erences Lcom and LIL3
share 91% sequence homology at the AA level (Fig. 1) [11].
Lcom and LIL3 belong to the class 1 cytokine receptor family
[12]. The extracellular regions of Lcom and LIL3 are predicted
to comprise of two cytokine receptor modules (CRM) each of
which is comprised of two ¢bronectin type III (FnIII) like
domains. These FnIII like domains consist of eight antipar-
allel beta pleated sheets. The beta pleated sheets for the mem-
brane distal FnIII like domain are commonly labeled A to H
and those for the membrane proximal FnIII like domain AP to
HP.
The low a⁄nity conversion displayed by Lcom for IL5 has
restricted work identifying contact points between the two
molecules. Previously such residues were identi¢ed as GM-
CSF contact points and then con¢rmed later as IL5 contact
points [9,10]. Although the glutamic acid in helix A provides a
common contact point with Lcom, the large di¡erence in a⁄n-
ity conversion suggests that there must be contact points on
Lcom unique to each cytokine.
The structural requirements of LIL3 and Lcom for ligand
interaction are poorly understood. Chimeras of Lcom and
LIL3 were used by Wang et al. [13] to identify the areas of
LIL3 which are able to bind IL3 in the absence of alpha chain.
In addition contact regions for IL3, GM-CSF and IL5 on the
human form of Lcom have been identi¢ed by comparison to
growth hormone receptor contact points [9,10].
This paper describes structure/function analyses of mLcom
and mLIL3 using biological activity as a measure of receptor
function. Chimeras of these two molecules were introduced
into CTLL2 cells expressing IL5RK (CTLL2-hIL5RK). Cells
expressing beta chain were selected by virtue of their ability to
proliferate in response to mIL3 and then tested for IL5 activ-
ity. It was found that mutation of LIL3 to Lcom sequence in the
region responsible for IL3 binding results in a beta chain that
is able to respond to IL5. This is the ¢rst identi¢cation of
residues on LIL3 that confer speci¢city to IL3. Furthermore,
it is the ¢rst identi¢cation of residues on mouse Lcom involved
in IL5 interaction.
2. Materials and methods
2.1. Construction of chimeric of beta chains
cDNA encoding Lcom and LIL3 in the vector pCDM8 were kindly
donated by Dr Angel Lopez and Dr Joanne Woodcock (Adelaide,
Australia). These were cloned into the mammalian expression vector
pEE6 [14]. Chimeras of Lcom and LIL3 were constructed using the
common HindIII site located near the junction of CRM1 and
CRM2 and the DraIII site located in the transmembrane region
(Fig. 2). cDNA encoding the extracytoplasmic region of LIL3 which
had been mutated from IPKY to MAYSF (residues 367 to 370) was a
kind gift of Dr Atsushi Miyajima (Tokyo, Japan). This was cloned
into pEE6 vector containing the intracytoplasmic region of Lcom at the
DraIII site within the transmembrane domain (LIL3-MAYSF).
2.2. Production of bulk stable transfectants with CTLL2-hIL5RK cells
106 CTLL2-hIL5RK cells were electroporated (960 WF, 260 V) with
15 Wg of pEE6 containing beta chain cDNA and 15 Wg of vector
encoding the mIL3RK (pSut-1 [15]). Cells were allowed to recover
from transfection in recovery medium (RPMI+10% FCS+200 U/ml
hIL2+2 Wl/ml baculovirus supernatant containing mIL3) before being
washed once (1100 rpm, 5 min) and resuspended in selection medium
(RPMI+10% FCS+20 Wl/ml baculovirus supernatant containing
mIL3). Once a healthy population of bulk stable transfectants was
obtained the cells were tested for IL5 responsiveness.
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2.3. Testing for IL5, IL3 and IL2 responsiveness
Bulk cultures were washed three times in RPMI+10% FCS to re-
move residual IL3. 1U104 cells in a 50 Wl volume were then added to
microplate wells containing 50 Wl of test substrate and incubated at
37‡C and 5% CO2. After 48 h, 10 Wl of RPMI+10% FCS containing
0.33 WCi of tritiated thymidine was added to each well and the cells
incubated a further 4 h at 37‡C and 5% CO2. The cells were then
harvested onto glass ¢ber ¢lters and level of tritiated thymidine in-
corporation determined on a Packard Matrix 9600 direct beta coun-
ter. For maximal proliferative response, 2500 ng/ml of mIL5 and
1/200 dilution of baculovirus supernatant containing mIL3 was
used. ED50 values for mIL3 and mIL5 were determined by ¢tting
the data to the equation y = a0+a1/(1+(x/a2)a3).
3. Results
3.1. Responsiveness of cells expressing chimeras of mLcom
and mLIL3 to mIL5
Cells expressing either mLcom=IL3 or mLIL3=com were able to
respond to mIL3 (Fig. 3). In contrast, only cells expressing the
mLIL3=com chimera were able to respond to mIL5. This indi-
cates that residues of mLIL3 restricting mIL5 activity are lo-
cated within the membrane proximal CRM.
3.2. Activity of the mLIL3-MAYSF mutant
Within this CRM of mLIL3 reside the residues responsible
for the ability of mLIL3 to bind to mIL3 in the absence of the
mIL3RK [13]. In addition, this area aligns with a contact
point for hIL5 on human Lcom [9]. It therefore seemed possible
that this region may also be responsible for the lack of IL5
activity displayed by LIL3.
The LIL3-MAYSF chimera encodes for LIL3 for the entire
extracellular region except for residues 367, 368, 369 and 370
which were mutated from IPKY to MAYSF. Cells expressing
this mutant were able to respond to mIL5, although this ac-
tivity was low compared to cells expressing Lcom.
3.3. Titrations of mIL5 and mIL3 on cells expressing beta
chains
Titrations with mIL3 and mIL5 were performed on cells
expressing chimeric and mutant beta chains to further assess
the relative ability of these molecules to interact with these
cytokines. All four forms of the beta chain had similar ED50
values in response to mIL3 (Fig. 4). The ED50 for cells ex-
pressing LIL3-MAYSF was higher than that for cells express-
ing mLcom or mLIL3=com indicating that this mutant had a
reduced ability to interact with mIL5 (Fig. 5). It was demon-
strated on three separate occasions that cells expressing LIL3-
MAYSF displayed an mIL5 ED50 3 to 4 times higher than
that of cells expressing mLcom (data not shown).
4. Discussion
CTLL2 cells are a cytotoxic T-lymphocyte derived cell line
which proliferate in the presence of IL2 and do not normally
respond to IL3 or IL5 as they lack the receptor components.
When the mIL3RK and either Lcom or LIL3 are cloned into
CTLL2 cells a line is produced that is capable of proliferating
in response to IL3 [16]. Similarly, the cloning of the IL5RK
and Lcom into these cells produces an IL5 responsive cell line
[17].
Here, CTLL2 cells into which had been cloned the hIL5RK
were used to measure the function of LIL3/Lcom chimeras. Bulk
stables expressing these chimeras were tested for their ability
to respond to IL5. The human form of the IL5RK was chosen
Fig. 1. Sequence comparison between the extracellular domains of mLIL3 (top) and mLcom (bottom). Only residues of mLIL3 di¡ering from
mLcom are displayed. Numbering is from the beginning of the leader sequence, however, only sequence of the mature peptide is displayed. The
regions belonging to CRM1 and 2 are boxed and the predicted beta pleated sheet regions of CRM2 are underlined and labeled in lower case.
The regions responsible for IL3 binding on LIL3 in the absence of IL3RK are highlighted [13]. The HindIII site used in chimera construction
and the beginning of the transmembrane domain are labeled.
Fig. 2. Schematic representation of chimeras of LIL3 and Lcom.
Hatched areas represent Lcom and clear areas represent LIL3 se-
quence. The approximate location of the MAYSF mutation to the
LIL3-MAYSF chimera, HindIII and DraIII sites used in cloning and
the CRMs are also labeled.
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as it is able to form a functional receptor with mLcom [18]. In
addition, unlike its murine counterpart, the hIL5RK is able to
interact with mIL5 and hIL5 with similar e⁄cacy [19].
Residues within the BP-CP loop region of CRM2 of the LIL3
were identi¢ed which restrict IL5 activity. Mutation of these
residues to the corresponding residues on Lcom resulted in a
molecule able to respond to IL5. Because the di¡erent stable
transfectants varied in response to IL3, it was necessary to
correct the IL5 response for the di¡erence in proliferation
capacity. This was done by expressing IL5 response as a per-
centage of the IL3 response (Table 1). This demonstrates that
LIL3-MAYSF is less able to be stimulated by IL5 than Lcom.
This reduction in activity is also re£ected in the ED50 for these
receptors. This demonstrates that there exist further regions of
mLcom that are involved in mIL5 interaction and lacked by
mLIL3. Such residues are likely to reside within CRM2 of the
molecule as LIL3=com responded normally to mIL5. Candidates
include the two other less signi¢cant contact points for mIL3
on mLIL3 identi¢ed by Wang et al. [13], Tyr-340 and Asp-422.
It should be noted that there may be variations between the
cell lines produced in this work. Thus the ability to compare
the IL5 activity of beta chain chimeras expressed on their
surface is limited. Using mIL3 activity as a control corrects
for the majority of such variations. However, mIL3 activity
su¡ers from two variables that have no bearing on IL5 activ-
ity. Firstly, LIL3-MAYSF has a higher a⁄nity for IL3 than
LIL3 as a result of two extra contact points at Tyr-340 and
Asp-422 [13]. Secondly, mIL3RK was introduced into CTLL2
(hIL5RK) cells at the same time as the beta chain. Therefore
variations may exist in IL3RK expression between cell lines.
Using uncloned bulk cultures, as done here, minimizes but
does not exclude these e¡ects.
Fig. 3. Maximum response levels for cells expressing wild-type and chimeric beta chains. Values represent levels of tritiated thymidine incorpo-
ration as described in Section 2. Increasing the concentration above these levels did not result in any increase in activity. Murine IL5 was tested
to a concentration of 22 125 ng/ml without any response from cells expressing mLIL3 or Lcom=IL3. Error bars represent one standard deviation
of triplicates. These results are representative of three separate experiments.
Fig. 5. Murine IL5 titration for cells expressing mLcom (E, line),
mLIL3=com (O, dotted line) and mLIL3-MAYSF (a, dashed line). Er-
ror bars represent one standard deviation of triplicates. Calculated
ED50 values for these curves can be seen in Table 1.
Fig. 4. Murine IL3 titration for cells expressing mLcom (E, line),
mLIL3=com (O, dotted line), mLcom=IL3 (7, dashed line, long dashes)
and mLIL3-MAYSF (a, dashed line, short dashes). Murine IL3 con-
centration is represented as a reciprocal dilution of baculovirus
supernatant containing mIL3. Error bars represent one standard de-
viation of triplicates. Calculated ED50 values for these curves can be
seen in Table 1.
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This work has identi¢ed a region of mLcom required for
mIL5 activity. The same region of mLIL3 is responsible for
mIL3 binding in the absence of the mIL3RK [13]. In addition
this region aligns to contact points on human Lcom for hIL5
and hGM-CSF but not hIL3 [9]. Thus, this region is an im-
portant structural motif of Lcom and LIL3 that plays a role in
both ligand interaction and speci¢city. By targeting this re-
gion, it may be possible to ¢nd compounds that alter the
activity of one cytokine without e¡ecting the others. This
could be an important approach for drug discovery. Antago-
nists to IL5 are potential anti-asthma drugs, whereas upregu-
lating IL3 and GM-CSF may be important in treating infec-
tious diseases and recovery from irradiation.
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Table 1
Values representing the di¡erence in activity between cell lines expressing various forms of beta chain in response to mIL5 and mIL3
Beta chain expressed Cytokine ED50 Max activity (103 CPS) % max activity (mIL5 vs. mIL3)
Lcom mIL5 6.3 ng/ml 16.6 þ 0.9 60%
mIL3 2426 27.4 þ 2.9
LIL3=com mIL5 6.6 ng/ml 45.1 þ 2.6 112%
mIL3 1493 39.9 þ 2.0
Lcom=IL3 mIL5 n.a. 0.05 þ 0.01 0%
mIL3 1770 21.4 þ 1.3
LIL3-MAYSF mIL5 22.4 ng/ml 3.5 þ 0.2 11%
mIL3 1436 19.3 þ 2.4
CPS, counts per second of incorporated tritiated thymidine; n.a., not applicable.
ED50 is expressed in ng/ml for mIL5 and as a reciprocal dilution of baculovirus supernatant containing mIL3. Maximum activity represents the
highest level of tritiated thymidine incorporation in response to the respective cytokine. Errors for maximum activity represent one standard de-
viation of triplicates. Percentage maximum activity represents the maximum mIL5 activity as a percentage of the maximum mIL3 activity.
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